What Is Glatiramer Acetate / What Is Mylan’s Glatiramer Acetate Injection?
Glatiramer acetate is a prescription medication that can be injected subcutaneously to treat relapsing forms of multiple sclerosis (MS). Every…
Mylan to Acquire the Global Marketing Rights to a Once-monthly Glatiramer Acetate Product through an Investment and Partnership with Israeli Company Mapi Pharma
Once approved, this product could represent a significant milestone for patients with relapsing-remitting multiple sclerosis Mapi Pharma has completed an…
Stuart Schlossman
Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with Secondary Progressive MS (SPMS)
Mar 23, 2018 EXPAND shows oral siponimod (BAF312) is the first potential therapy to meaningfully delay disability progression in typical…
Stuart Schlossman
Merck’s MS Therapy Evobrutinib Significantly Reduces Brain Lesions, Phase 2 Trial Shows
Merck KGaA’s evobrutinib led to significant reductions in relapsing multiple sclerosis patients’ brain and spinal cord lesions, compared with a placebo,…
Stuart Schlossman
Alemtuzumab-induced autoimmunity: getting closer to answers
Publish date: March 6, 2018 By Damian McNamara Clinical Neurology News EXPERT ANALYSIS FROM ACTRIMS FORUM 2018 SAN DIEGO –…
Stuart Schlossman
FDA approves Glatopa 40 mg/mL generic option for relapsing MS
Feb 2018 Sandoz announced the FDA approval and launch of Glatopa (glatiramer acetate injection) 40 mg/mL. Glatopa 40 mg/mL is…
Stuart Schlossman
Breaking News: MS Drug Daclizumab Pulled from Worldwide Market
by Judy George, Contributing Writer, MedPage TodayMarch 02, 2018 Biogen and Abbvie voluntarily pulled the multiple sclerosis drug daclizumab (Zinbryta) from the worldwide market…
Stuart Schlossman
Ocrevus Significantly Decreases Disease Activity in MS Patients, Study Shows
FEBRUARY 27, 2017 – BY PATRICIA INACIO, PHD Ocrevus (ocrelizumab), an investigational monoclonal antibody, significantly decreases disease activity in patients with…
Stuart Schlossman
video: Aaron Boster, MD, discusses patient-centered MS treatment
February 2018 :::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::::: MS Views and News is MAKING an IMPACT for those, affected by Multiple Sclerosis MS Views and News provides…
Stuart Schlossman
MS Drug Poses Hard Choices for Women Wanting Kids
By Dennis Thompson HealthDay Reporter THURSDAY, Feb. 8, 2018 (HealthDay News) — A powerful multiple sclerosis drug presents women with a tough…
Stuart Schlossman
